Last reviewed · How we verify

RCHOP o R-miniCHOP at standard doses

Fondazione Italiana Linfomi - ETS · Phase 3 active Small molecule

RCHOP o R-miniCHOP at standard doses is a CD20-targeting monoclonal antibody in combination with chemotherapy Small molecule drug developed by Fondazione Italiana Linfomi - ETS. It is currently in Phase 3 development for Follicular lymphoma, Diffuse large B-cell lymphoma.

R-CHOP and R-miniCHOP combine chemotherapy and a monoclonal antibody targeting CD20 on B cells.

R-CHOP and R-miniCHOP combine chemotherapy and a monoclonal antibody targeting CD20 on B cells. Used for Follicular lymphoma, Diffuse large B-cell lymphoma.

At a glance

Generic nameRCHOP o R-miniCHOP at standard doses
SponsorFondazione Italiana Linfomi - ETS
Drug classCD20-targeting monoclonal antibody in combination with chemotherapy
TargetCD20
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Rituximab targets CD20, a protein on B cells, while cyclophosphamide, doxorubicin, vincristine, and prednisone are chemotherapy agents. This combination is used to treat various types of non-Hodgkin lymphoma.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RCHOP o R-miniCHOP at standard doses

What is RCHOP o R-miniCHOP at standard doses?

RCHOP o R-miniCHOP at standard doses is a CD20-targeting monoclonal antibody in combination with chemotherapy drug developed by Fondazione Italiana Linfomi - ETS, indicated for Follicular lymphoma, Diffuse large B-cell lymphoma.

How does RCHOP o R-miniCHOP at standard doses work?

R-CHOP and R-miniCHOP combine chemotherapy and a monoclonal antibody targeting CD20 on B cells.

What is RCHOP o R-miniCHOP at standard doses used for?

RCHOP o R-miniCHOP at standard doses is indicated for Follicular lymphoma, Diffuse large B-cell lymphoma.

Who makes RCHOP o R-miniCHOP at standard doses?

RCHOP o R-miniCHOP at standard doses is developed by Fondazione Italiana Linfomi - ETS (see full Fondazione Italiana Linfomi - ETS pipeline at /company/fondazione-italiana-linfomi-ets).

What drug class is RCHOP o R-miniCHOP at standard doses in?

RCHOP o R-miniCHOP at standard doses belongs to the CD20-targeting monoclonal antibody in combination with chemotherapy class. See all CD20-targeting monoclonal antibody in combination with chemotherapy drugs at /class/cd20-targeting-monoclonal-antibody-in-combination-with-chemotherapy.

What development phase is RCHOP o R-miniCHOP at standard doses in?

RCHOP o R-miniCHOP at standard doses is in Phase 3.

What are the side effects of RCHOP o R-miniCHOP at standard doses?

Common side effects of RCHOP o R-miniCHOP at standard doses include Neutropenia, Thrombocytopenia, Anemia, Infections, Fatigue.

What does RCHOP o R-miniCHOP at standard doses target?

RCHOP o R-miniCHOP at standard doses targets CD20 and is a CD20-targeting monoclonal antibody in combination with chemotherapy.

Related